ASN51

DRUG5 trials

Sponsors

Asceneuron Pty Ltd., Asceneuron S.A.

Conditions

Alzheimer DiseaseDrug Drug InteractionHealthyHealthy Participants

Phase 1

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

TerminatedNCT04759365

Asceneuron Pty Ltd.Alzheimer Disease

Start: 2021-06-02End: 2022-08-01Updated: 2023-01-17

PET Study of Repeated ASN51 in Healthy Volunteers

CompletedNCT05725005

Asceneuron S.A.Healthy

Start: 2023-01-26End: 2023-06-08Updated: 2025-05-08

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

CompletedNCT06232109

Asceneuron S.A.Drug Drug Interaction

Start: 2024-02-22End: 2024-07-03Updated: 2024-12-18

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

CompletedNCT06390098

Asceneuron S.A.Healthy Participants

Start: 2021-08-09End: 2021-10-12Updated: 2025-05-08

Phase 2

Study of ASN51 in Adults With Early Alzheimer's Disease

TerminatedNCT06677203

Asceneuron S.A.Alzheimer Disease

Start: 2024-10-16End: 2024-11-08Updated: 2025-06-29